PECAM1 and neoplasm: To assess the mechanism by which the sorafenib/MI-319 combination impaired tumor growth, tumor tissue sections were examined by H&E staining for necrosis, IHC for proliferation (Ki-67) and microvessel density (CD31), and by TUNEL assay.